Achim Rittmeyer

T-DXd bij HER2-gemuteerde NSCLC: systemische en intracraniële werkzaamheid en veiligheid

Journal of Thoracic Oncology · 24 februari 2026

Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Fase III IPSOS Study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025-12

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 juli 2025

Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to Eerstelijns Pembro...

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025-02

Tiragolumab plus atezolizumab plus chemo bij uitgebreid SCLC: SKYSCRAPER-02 fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 januari 2024

Eerstelijns atezolizumab mono versus chemotherapie bij NSCLC: IMpower110 langetermijn

Lancet (London, England) · 5 augustus 2023

Atezolizumab versus docetaxel bij NSCLC: IMpower210 definitief

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021-01

Atezolizumab plus carboplatine-nab-paclitaxel versus chemotherapie bij NSCLC: IMpower130 fase III

The Lancet. Oncology · 2019-07

Atezolizumab doorbehandelen na progressie bij NSCLC: OAK analyse

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018-12

Geactualiseerde OAK-analyse: atezolizumab versus docetaxel bij gevorderd NSCLC

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018-08

Atezolizumab versus docetaxel bij eerder behandeld NSCLC: OAK fase III-studie

Lancet (London, England) · 21 januari 2017

Atezolizumab versus docetaxel bij eerder behandeld NSCLC: POPLAR fase II

Lancet (London, England) · 30 april 2016

Publicaties op Oncologisch.com